Genetically stable live attenuated respiratory syncytial virus vaccine and its production

Abstract

Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.

1 . A vaccine, comprising an immunologically effective amount of a recombinant infectious respiratory syncytial virus comprising a large polymerase protein (L), phosphoprotein (P), nucleocapsid protein (N) and a M2-1 protein and a genome or antigenome having a deletion of the codon that encodes the serine at position 1313, or a corresponding position, of the L protein, and optionally comprises nonstructural protein 1 (NS1), nonstructural protein 2 (NS2), glycoprotein (G), fusion protein (F), matrix protein (M), M2-2 protein, and small hydrophobic protein (SH). 
     
     
         2 . The vaccine of  claim 1 , wherein the virus is attenuated. 
     
     
         3 . The vaccine of  claim 1 , wherein the viral genome or antigenome further comprises a mutation of the codon that encodes the tyrosine at position 1321, or a corresponding position, of the L protein. 
     
     
         4 . The vaccine of  claim 1 , wherein the viral genome or antigenome further comprises a deletion of the NS2 gene. 
     
     
         5 . The vaccine of  claim 1 , wherein the viral genome or antigenome further comprises one or more of the following mutations:
 the L protein mutation of 1321K, 1321E, 1321P, 1321G, 1321K(AAA), 1321E(GAA), 1321P(CCT), 1321G(GGA), or 1321G(GGT);   the L protein mutation Q831L;   V267I in the N protein, E218A in the F protein, T523 I in the F protein, C319Y in the L protein, and H1690Y in the L protein;   a T to C substitution at the ninth nucleotide position of the gene-start signal of the M2 gene, which corresponds to nucleotide 7606 of a positive sense complement of the genome of RSV strain A2; and   deletion of the SH gene.   
     
     
         6 . The vaccine of  claim 1 , wherein the viral genome or antigenome further comprises:
 a mutation of the codon that encodes the tyrosine at position 1321, or a corresponding position, of the L protein, wherein the mutation of the codon is an AAA mutation.   
     
     
         7 . The vaccine of  claim 1 , wherein the viral genome or antigenome further comprises:
 a mutation of the codon that encodes the tyrosine at position 1321, or a corresponding position, of the L protein, wherein the mutation of the codon is an AAA mutation;   V267I in the N protein, E218A and T523I in the F protein, and C319Y and H1690Y in the L protein; and   a deletion of the SH gene.   
     
     
         8 . The vaccine of  claim 1 , wherein the viral genome or antigenome further comprises a mutation of amino acid sequence residue 1314, or a corresponding position, of the L protein, wherein the mutation of L protein amino acid sequence residue 1314 is an amino acid substitution of leucine for isoleucine. 
     
     
         9 . The vaccine of  claim 8 , wherein the mutation of L protein amino acid sequence residue 1314 is encoded by the codon CTG. 
     
     
         10 . The vaccine of  claim 8 , wherein the virus is attenuated. 
     
     
         11 . The vaccine of  claim 8 , wherein the viral genome or antigenome further comprises a mutation of the codon that encodes a tyrosine at position 1321, or a corresponding position, of the L protein. 
     
     
         12 . The vaccine of  claim 8 , wherein the viral genome or antigenome further comprises a deletion of the NS2 gene. 
     
     
         13 . The vaccine of  claim 8 , wherein the viral genome or antigenome further comprises one or more of the following mutations:
 the L protein mutation of 1321K, 1321E, 1321P, 1321G, 1321K(AAA), 1321E(GAA), 1321P(CCT), 1321G(GGA), or 1321G(GGT);   the L protein mutation Q831L;   V2671 in the N protein, E218A in the F protein, T5231 in the F protein, C319Y in the L protein, and H1690Y in the L protein;   a T to C substitution at the ninth nucleotide position of the gene-start signal of the M2 gene, which corresponds to nucleotide 7606 of a positive sense complement of the genome of RSV strain A2; and   deletion of the SH gene.   
     
     
         14 . A method of producing an immune response to a viral protein, comprising administering the vaccine of  claim 1  to an animal. 
     
     
         15 . The method of  claim 14 , wherein the vaccine is administered via injection, aerosol delivery, nasal spray, nasal droplets, oral inoculation, or topical application. 
     
     
         16 . The method of  claim 14 , wherein the animal is a mammal. 
     
     
         17 . The method of  claim 16 , wherein the mammal is a human. 
     
     
         18 . A vaccine comprising an effective amount of a recombinant infectious respiratory syncytial virus comprising a large polymerase protein (L), phosphoprotein (P), nucleocapsid protein (N), a M2-1 protein nonstructural protein 1 (NS1), a glycoprotein (G), a fusion protein (F), a matrix protein (M), a M2-2 protein, and a small hydrophobic protein (SH), and a genome or antigenome having:
 a deletion of the codon that encodes the serine at position 1313, or a corresponding position, of the L protein,   a mutation of amino acid sequence residue 1314, or a corresponding position, of the L protein, wherein the mutation of L protein amino acid sequence residue 1314 is an amino acid substitution of leucine for isoleucine, wherein the leucine is encoded by a codon set forth as CTG; and   a deletion of the NS2 gene.   
     
     
         19 . A method of producing an immune response to a viral protein, comprising administering the vaccine of  claim 18  to an animal. 
     
     
         20 . The method of  claim 19 , wherein the vaccine is administered via injection, aerosol delivery, nasal spray, nasal droplets, oral inoculation, or topical application. 
     
     
         21 . The method of  claim 19 , wherein the animal is a mammal. 
     
     
         22 . The method of  claim 21 , wherein the mammal is a human.